JP2022529700A5 - - Google Patents
Info
- Publication number
- JP2022529700A5 JP2022529700A5 JP2021562085A JP2021562085A JP2022529700A5 JP 2022529700 A5 JP2022529700 A5 JP 2022529700A5 JP 2021562085 A JP2021562085 A JP 2021562085A JP 2021562085 A JP2021562085 A JP 2021562085A JP 2022529700 A5 JP2022529700 A5 JP 2022529700A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- alkyl
- formula
- pharmaceutically acceptable
- cocrystal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962837331P | 2019-04-23 | 2019-04-23 | |
| US62/837,331 | 2019-04-23 | ||
| PCT/US2020/029483 WO2020219650A1 (en) | 2019-04-23 | 2020-04-23 | Degraders of cyclin-dependent kinase 12 (cdk12) and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022529700A JP2022529700A (ja) | 2022-06-23 |
| JP2022529700A5 true JP2022529700A5 (https=) | 2023-05-01 |
Family
ID=72941778
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021562085A Pending JP2022529700A (ja) | 2019-04-23 | 2020-04-23 | サイクリン依存性キナーゼ１２（ｃｄｋ１２）の分解剤およびその使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20220227734A1 (https=) |
| EP (1) | EP3958861A4 (https=) |
| JP (1) | JP2022529700A (https=) |
| CN (1) | CN113993519B (https=) |
| AU (1) | AU2020263390B2 (https=) |
| CA (1) | CA3132387A1 (https=) |
| WO (1) | WO2020219650A1 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018165520A1 (en) | 2017-03-10 | 2018-09-13 | Vps-3, Inc. | Metalloenzyme inhibitor compounds |
| CA3141826A1 (en) | 2019-05-31 | 2020-12-03 | Ikena Oncology, Inc. | Tead inhibitors and uses thereof |
| CA3142351A1 (en) | 2019-05-31 | 2020-12-03 | Ikena Oncology, Inc. | Tead inhibitors and uses thereof |
| CA3142713A1 (en) | 2019-06-03 | 2020-12-10 | Regents Of The University Of Minnesota | Compounds that degrade kinases and uses thereof |
| AU2020321955A1 (en) | 2019-07-30 | 2022-03-17 | Eikonizo Therapapeutics, Inc. | HDAC6 inhibitors and uses thereof |
| WO2022120355A1 (en) * | 2020-12-02 | 2022-06-09 | Ikena Oncology, Inc. | Tead degraders and uses thereof |
| KR20240020735A (ko) | 2021-05-07 | 2024-02-15 | 카이메라 쎄라퓨틱스 인코포레이티드 | Cdk2 분해제 및 그 용도 |
| IL312013A (en) * | 2021-10-14 | 2024-06-01 | Cullgen Shanghai Inc | Modified proteins and protein degraders |
| US12084453B2 (en) | 2021-12-10 | 2024-09-10 | Incyte Corporation | Bicyclic amines as CDK12 inhibitors |
| WO2023143482A1 (zh) * | 2022-01-29 | 2023-08-03 | 上海辉启生物医药科技有限公司 | 2-氨基嘧啶类化合物或其盐及其制备方法和用途 |
| TW202345813A (zh) | 2022-04-08 | 2023-12-01 | 美商艾科尼佐療法股份有限公司 | 㗁二唑ｈｄａｃ６抑制劑及其用途 |
| WO2024183798A1 (en) * | 2023-03-07 | 2024-09-12 | Cullgen Inc. | Compounds and methods of treating cancers |
| CN119950745B (zh) * | 2025-01-14 | 2025-10-17 | 浙江大学 | 一种药物组合物及其在制备抗肿瘤药物中的应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102668696B1 (ko) * | 2012-01-12 | 2024-05-29 | 예일 유니버시티 | E3 유비퀴틴 리가아제에 의한 표적 단백질 및 다른 폴리펩티드의 증진된 분해를 위한 화합물 및 방법 |
| WO2015058126A1 (en) * | 2013-10-18 | 2015-04-23 | Syros Pharmaceuticals, Inc. | Heteroaromatic compounds useful for the treatment of prolferative diseases |
| CA2927924A1 (en) * | 2013-10-18 | 2015-04-23 | Syros Pharmaceuticals, Inc. | Heteroaromatic compounds useful for the treatment of proliferative diseases |
| CN110229142A (zh) * | 2014-04-04 | 2019-09-13 | 希洛斯医药品股份有限公司 | 细胞周期蛋白依赖性激酶7(cdk7)的抑制剂 |
| US9694084B2 (en) * | 2014-12-23 | 2017-07-04 | Dana-Farber Cancer Institute, Inc. | Methods to induce targeted protein degradation through bifunctional molecules |
| EP3445765A4 (en) * | 2016-04-22 | 2019-09-18 | Dana Farber Cancer Institute, Inc. | DECREASE OF CYCLINE-DEPENDENT KINASE 4/6 (CDK4 / 6) BY CONJUGATION OF CDK4 / 6 INHIBITORS WITH E3-LIGASE LIGANDS AND METHODS OF USE |
| CA3018429A1 (en) * | 2016-04-22 | 2017-10-26 | Dana-Farber Cancer Institute, Inc. | Degradation of cyclin-dependent kinase 9 (cdk9) by conjugation of cdk9 inhibitors with e3 ligase ligand and methods of use |
| AU2017295863B2 (en) * | 2016-07-13 | 2022-07-07 | Medic Life Sciences, Inc. | Inhibitors of cyclin-dependent kinase 7 (CDK7) |
| AU2017363307B2 (en) * | 2016-11-22 | 2021-07-29 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 12 (CDK12) and uses thereof |
| AU2019309909A1 (en) * | 2018-07-23 | 2021-02-04 | Dana-Farber Cancer Institute, Inc. | Degradation of cyclin-dependent kinase 4/6 (CDK4/6) by conjugation of CDK4/6 inhibitors with E3 ligase ligand and methods of use |
-
2020
- 2020-04-23 WO PCT/US2020/029483 patent/WO2020219650A1/en not_active Ceased
- 2020-04-23 CA CA3132387A patent/CA3132387A1/en active Pending
- 2020-04-23 EP EP20795755.6A patent/EP3958861A4/en active Pending
- 2020-04-23 CN CN202080044331.9A patent/CN113993519B/zh active Active
- 2020-04-23 JP JP2021562085A patent/JP2022529700A/ja active Pending
- 2020-04-23 US US17/604,852 patent/US20220227734A1/en active Pending
- 2020-04-23 AU AU2020263390A patent/AU2020263390B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022529700A5 (https=) | ||
| KR102505664B1 (ko) | Ezh2 저해제 및 e3 리가제 바인더를 포함하는 화합물 및 이를 유효성분으로 함유하는 ezh2 관련 질환의 예방 또는 치료용 약학적 조성물 | |
| ES2561598T3 (es) | Derivados de indazol sustituidos con benzodioxinilo | |
| JP2020533288A5 (https=) | ||
| JP2022507020A5 (https=) | ||
| CA2810706C (en) | Substituted amide compound | |
| ES2552684T3 (es) | Nuevos compuestos de imidazolidina como moduladores del receptor de andrógenos | |
| JP2022541467A (ja) | オーロラキナーゼ阻害剤およびその使用 | |
| JP2021523225A5 (https=) | ||
| EP3119781B1 (en) | Compounds which inhibit rna polymerase, compositions including such compounds, and their use | |
| EP4050008A1 (en) | Pyridazinone or pyridazine compound and derivative and pharmaceutical composition thereof | |
| JP2020517595A (ja) | サイクリン依存性キナーゼｃｄｋ９の新規阻害剤 | |
| JP2022548250A5 (https=) | ||
| WO2019012172A1 (es) | Nuevos derivados heteroaryl amida como inhibidores selectivos de histona deacetilasa 1 y 2 (hdac1/2) | |
| FR2943669A1 (fr) | Derives de nicotinamide,leur preparation et leur application en therapeutique | |
| JP2017504595A5 (https=) | ||
| US11932631B2 (en) | Process for preparing aficamten | |
| JP2013542267A5 (https=) | ||
| DK2657227T3 (en) | Novel substituted isoquinoline derivative | |
| JP2021534254A5 (ja) | 心臓弁疾患を治療するための医薬組成物 | |
| JP2021529174A5 (https=) | ||
| JP2024517183A5 (https=) | ||
| CZ2003239A3 (cs) | Způsob přípravy azacykloalkanoylaminothiazolů | |
| JP2021534084A5 (https=) | ||
| ES2991258T3 (es) | Procedimientos y productos intermedios para producir compuestos de diazaespiro-lactama |